ARS-Patent protected Novo Nordisk A/S’s interests in a patent dispute

ARS-Patent represented the interests of Novo Nordisk A/S in the patent dispute over the Rospatent’s decision on extension of the validity term of a patent related to Insulin degludec owned by Novo Nordisk A/S. Recently, a request of the plaintiff (Geropharm LLC) for the cassation appeal to be considered by the Court Board of the Supreme Court of the Russian Federation was rejected. That was the final step of the case.

During the legal proceedings, Kirill Osipov, the Head of Legal Department, being the authorized representative of the patentee showed the Court for Intellectual Property Rights, which considered Geropharm’s lawsuit as the first-instance court, that the term for filing such lawsuit as set by Russian law was missed by the plaintiff. In view of arguments and pieces of evidence provided, the Court rejected the lawsuit. The Court’s decision was also upheld by further court instances.

The case was widely discussed in the mass-media.

Make an enquiry